

Mitoxantrone in multiple sclerosis

Sir,

I read the article 'Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting'^[1] with interest. I applaud the authors for conducting such a study in Indian setup. The beneficence of low cost involved in the treatment of multiple sclerosis with mitoxantrone need to be evaluated against the cost involved in dealing with the significant morbidity caused due to potential side effects of the drug therapy. The ethical justification of initiating such therapy in relatively milder form of disease is a matter of serious discussion and will be debated upon for a long time to come. Nonetheless, the authors have done a commendable job in view of patients seriously impaired by multiple sclerosis who cannot afford first line treatment, though large

scale study will be needed to complement the results of this study.

Sourabh Aggarwal

University College of Medical Sciences, New Delhi, India.

E-mail: drsourabh79@gmail.com

DOI: 10.4103/0028-3886.59504

Reference

1. Singhal BS, Geeta S, Hundalani SG, Menon S. Efficacy and safety of Mitoxantrone, as an initial therapy, in multiple sclerosis: Experience in an Indian tertiary care setting. *Neurol India* 2009;57:418-23.

Accepted on 15-12-2009